Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 334

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 334
---
 — |     |              | — |     |              | 13,821 | -1 |     |       |    613,821 |    |
| Chief Financial Officer, Senior Vice President and Secretary |     |      | 2023 |     |        |   470,676 |     |       | — |     |        | — |     |        | 1,427,260 |     |              | — |     |              | — |     |              |  2,769 |    |     |       |  1,900,705 | -4 |

| (1) | Represents (a) matching contributions made to the named executive officer under the Company’s 401(k) 
 plan and (b) life insurance premiums paid by the Company for his benefit.                            |

214

| (2) | Represents (a) matching contributions made to Mr. Shah under the Company’s 401(k) plan,               
 (b) accrued unused paid time off and (c) life insurance premiums paid by the Company for his benefit. |

| (3) | Represents compensation expense allocated by Sorrento to (and paid by) the Company for services provided by 
 Dr. Ji (on behalf of Sorrento) to the Company in January 2023.                                              |

| (4) | Mr. Ma was appointed as our Chief Financial Officer, Senior Vice President and Secretary on                                                                                                                                                        
 September 22, 2023. Represents compensation paid or accrued as our Chief Accounting Officer (from May 2023 until his appointment as our Chief Financial Officer, Senior Vice President and Secretary in September 2023) and as our Chief Financial 
 Officer.                                                                                                                                                                                                                                           |

Narrative Disclosure to Summary Compensation Table Arrangements with Executive Officers Scilex has entered into an offer letter with Mr. Shah. The material terms of the offer letter are described below. Shah Offer Letter and Compensation Scilex entered into an offer letter with Mr. Shah (the “Shah Offer Letter”), dated April 19, 2019, pursuant to which Mr. Shah serves as the Chief Executive Officer of Scilex Pharma. Under the Shah Offer Letter, Mr. Shah’s annual base salary was initially set at $407,925, which was increased to $579,280 in 2020 and to $792,000 on November 11, 2022 (but became effective as of March 17, 2022). On September 22, 2023, our Compensation Committee